Precision BioSciences reports first clinical evidence of cccDNA elimination in HBV; Q2 net loss $32.7M

PRECISION BIOSCIENCES INC

2026-Q2 EPS reported -$2.02 revenue$10,838,000

Liver biopsy showed 1-log reduction in cccDNA with <1% remaining after two PBGENE-HBV doses.
pgRNA became undetectable in 100% of evaluable patients; sustained up to six months.
Cash balance $112.4M as of June 30, 2026; expected to fund milestones through 2028.
Net loss $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025; non-cash warrant loss drove increase.
Alex Kelly promoted to COO; Naresh Tanna promoted to CFO; Cassie Gorsuch now leads all research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.